RU2010101093A - Способы диагностики и лечения рака - Google Patents

Способы диагностики и лечения рака Download PDF

Info

Publication number
RU2010101093A
RU2010101093A RU2010101093/10A RU2010101093A RU2010101093A RU 2010101093 A RU2010101093 A RU 2010101093A RU 2010101093/10 A RU2010101093/10 A RU 2010101093/10A RU 2010101093 A RU2010101093 A RU 2010101093A RU 2010101093 A RU2010101093 A RU 2010101093A
Authority
RU
Russia
Prior art keywords
subject
rrm1
cancer
expression
level
Prior art date
Application number
RU2010101093/10A
Other languages
English (en)
Russian (ru)
Inventor
Джерольд БЕПЛЕР (US)
Джерольд БЕПЛЕР
Original Assignee
Юниверсити Оф Саут Флорида (Us)
Юниверсити Оф Саут Флорида
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Оф Саут Флорида (Us), Юниверсити Оф Саут Флорида filed Critical Юниверсити Оф Саут Флорида (Us)
Publication of RU2010101093A publication Critical patent/RU2010101093A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2010101093/10A 2007-06-15 2008-06-13 Способы диагностики и лечения рака RU2010101093A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US94415707P 2007-06-15 2007-06-15
US60/944,157 2007-06-15
US3955508P 2008-03-26 2008-03-26
US61/039,555 2008-03-26

Publications (1)

Publication Number Publication Date
RU2010101093A true RU2010101093A (ru) 2011-07-20

Family

ID=40156627

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010101093/10A RU2010101093A (ru) 2007-06-15 2008-06-13 Способы диагностики и лечения рака

Country Status (12)

Country Link
US (1) US20090017012A1 (cg-RX-API-DMAC7.html)
EP (1) EP2171086B1 (cg-RX-API-DMAC7.html)
JP (1) JP5479332B2 (cg-RX-API-DMAC7.html)
KR (1) KR20100044780A (cg-RX-API-DMAC7.html)
CN (1) CN101815793A (cg-RX-API-DMAC7.html)
AU (1) AU2008266048A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0813364A2 (cg-RX-API-DMAC7.html)
CA (1) CA2690865A1 (cg-RX-API-DMAC7.html)
ES (1) ES2401475T3 (cg-RX-API-DMAC7.html)
MX (1) MX2009013646A (cg-RX-API-DMAC7.html)
RU (1) RU2010101093A (cg-RX-API-DMAC7.html)
WO (1) WO2008157353A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1877569A4 (en) * 2005-05-04 2009-07-15 Univ South Florida PREDICTING THE RESPONSE TO TREATMENT OF CANCER PATIENTS
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
BRPI0711011A2 (pt) 2006-05-18 2011-08-23 Molecular Profiling Institute, Inc. método para a determinação da intervenção médica para um estado de doença, método para a identificação de uma terapia de droga com capacidade de interação com um alvo molecular e sistema para a determinação da intervenção médica individualizada para um estado de doença
EP2730662A1 (en) * 2008-11-12 2014-05-14 Caris Life Sciences Luxembourg Holdings Methods and systems of using exosomes for determining phenotypes
WO2011109440A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
JP5024736B2 (ja) 2009-10-15 2012-09-12 住友電気工業株式会社 発電システム
US9393318B2 (en) 2010-03-29 2016-07-19 Abraxis Bioscience, Llc Methods of treating cancer
US10660965B2 (en) 2010-03-29 2020-05-26 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
KR101602532B1 (ko) * 2013-08-29 2016-03-11 경북대학교 산학협력단 위암의 재발 가능성 예측을 위한 정보제공 방법
US20180312928A1 (en) * 2015-10-26 2018-11-01 Cipherome Method and system for selecting customized drug using genomic nucleotide sequence variation information and survival information of cancer patient
AU2021305654A1 (en) * 2020-07-10 2023-03-02 Progenics Pharmaceuticals, Inc Methods of making prostate cancer treatment decisions
CN113957145B (zh) * 2021-10-19 2023-09-26 中国医学科学院肿瘤医院 m6A相关lncRNA在预测小细胞肺癌预后和化疗反应的应用
CN114564622B (zh) * 2022-03-03 2025-07-25 苏州良医汇网络科技有限公司 一种tnm分期表录入系统的方法、装置以及设备

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705336A (en) * 1995-03-07 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Assay for sensitivity of tumors to DNA-platinating chemotherapy
US20020090642A1 (en) * 1995-12-11 2002-07-11 Patrick G. Johnston Methods for determining the prognosis of breast cancer using antibodies specific for thymidylate synthase
WO1998033518A1 (en) * 1997-02-04 1998-08-06 Sloan-Kettering Institute For Cancer Research Mutants of thymidylate synthase and uses thereof
US6087489A (en) * 1998-06-02 2000-07-11 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of human thymidylate synthase expression
AU5569600A (en) * 1999-06-28 2001-01-31 Yusuke Nakamura Novel protein and dna thereof
US6248535B1 (en) * 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US6518416B1 (en) * 2000-12-01 2003-02-11 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US7049059B2 (en) * 2000-12-01 2006-05-23 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
US6582919B2 (en) * 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US6956111B2 (en) * 2001-03-02 2005-10-18 Response Genetics, Inc. Method of determining dihydropyrimidine dehydrogenase gene expression
US6686155B2 (en) * 2001-06-14 2004-02-03 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
US7919235B2 (en) * 2002-09-30 2011-04-05 F. Hoffman-La Roche Ag Oligonucleotides for genotyping thymidylate synthase gene
JP2007507770A (ja) * 2003-09-29 2007-03-29 パスワーク インフォーマティクス，インコーポレーテッド 生物学的特徴を検出するためのシステムおよび方法
EP1877569A4 (en) * 2005-05-04 2009-07-15 Univ South Florida PREDICTING THE RESPONSE TO TREATMENT OF CANCER PATIENTS

Also Published As

Publication number Publication date
KR20100044780A (ko) 2010-04-30
ES2401475T3 (es) 2013-04-19
CA2690865A1 (en) 2008-12-24
AU2008266048A1 (en) 2008-12-24
JP2010530746A (ja) 2010-09-16
JP5479332B2 (ja) 2014-04-23
CN101815793A (zh) 2010-08-25
WO2008157353A1 (en) 2008-12-24
EP2171086A4 (en) 2010-10-13
EP2171086A1 (en) 2010-04-07
BRPI0813364A2 (pt) 2014-12-30
MX2009013646A (es) 2010-03-30
EP2171086B1 (en) 2012-12-19
US20090017012A1 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
RU2010101093A (ru) Способы диагностики и лечения рака
US8153380B2 (en) Gene expression markers for colorectal cancer prognosis
ES2488845T5 (es) Predicción de la probabilidad de recidiva de cáncer
US10179936B2 (en) Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
Pu et al. Circulating miR‐221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression
US8067178B2 (en) Gene expression markers for prediction of patient response to chemotherapy
ES2741745T3 (es) Método para usar la expresión génica para determinar el pronóstico de cáncer de próstata
JP2010530746A5 (cg-RX-API-DMAC7.html)
EP2140020A2 (en) Gene expression markers for prediction of patient response to chemotherapy
CN107488726A (zh) 一种肾癌预后评估生物标志物及其检测试剂和应用
CN106119347B (zh) 基于血清exosomal microRNAs的结直肠癌转移检测的引物和试剂盒
Laurenti et al. Comparison of ZAP-70/Syk mRNA levels with immunoglobulin heavy-chain gene mutation status and disease progression in chronic lymphocytic leukemia
US10934590B2 (en) Biomarkers for breast cancer and methods of use thereof
CN110257514A (zh) 一种新的食管癌血液miRNA标志物及其应用
CN118922561A (zh) 肾癌诊断用尿液miRNA标志物、诊断试剂及试剂盒
CN104630380B (zh) 碳酸酐酶iv在制备肺腺癌诊断制剂中的应用
CN121137157A (zh) 一种评估上皮性卵巢癌复发风险的试剂的用途
CN119464492A (zh) 一种急性髓系白血病预后评估的生物标志物、模型、系统及其应用
CN115896290A (zh) Trim21基因检测在肿瘤诊断、治疗选择和预后评估中的应用
WO2022103947A2 (en) Lactotransferrin and mif promoter polymorhpism detection for cancer detection and treatment
HK1166350A (en) Gene expression markers for colorectal cancer prognosis
HK1120089B (en) Gene expression markers for colorectal cancer prognosis
HK1167004A (en) Gene expression markers for colorectal cancer prognosis
HK1165507A (en) Gene expression markers for colorectal cancer prognosis
HK1165504A (en) Gene expression markers for colorectal cancer prognosis

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20130128